论文部分内容阅读
食管癌单用放疗的五年生存率仍很低。Wada 等曾首次报道博莱霉素用于食管癌的治疗,有50～70%患者获得显著的抗癌作用。本文报道苏联实验及临床肿瘤研究所放射科于1972～1973年间采用放疗和博莱霉素综合治疗食管癌共15例,其中13例鳞状细胞癌,1例癌性细胞和1例低度分化癌。癌肿位于食管中段14例和下段1例,15例中仅2例为Ⅱ期及癌肿长度5厘米,其余患者为Ⅲ期和Ⅳ期。4例有淋巴结转移(锁骨上1例、纵隔2例和腹腔1例)。3例有严重的食管狭窄,于治疗前作胃造瘘。15例中9例体重减轻8～9公斤。治疗时大多数患者已有癌肿的播散。
The five-year survival rate for radiotherapy alone for esophageal cancer is still very low. Wada et al. have reported for the first time that bleomycin is used in the treatment of esophageal cancer, and 50 to 70% of patients receive significant anti-cancer effects. In this paper, 15 cases of esophageal cancer treated with radiotherapy and bleomycin were treated between 1972 and 1973 in the Department of Radiology of the Soviet Academy of Experimental and Clinical Oncology. Among them, 13 cases were squamous cell carcinoma, 1 case of cancerous cells and 1 case of low-grade differentiation carcinoma. . Cancer was located in 14 cases in the middle esophagus and 1 in the lower segment. Only 2 cases in 15 cases were stage II and the length of the cancer was 5 cm. The remaining patients were in stage III and IV. Four patients had lymph node metastasis (1 in supraclavicular, 2 in mediastinum, and 1 in abdominal cavity). Three patients had severe esophageal stenosis and had stomach fistula before treatment. Of the 15 cases, 9 cases lost 8 to 9 kg. At the time of treatment, most patients had disseminated cancer.